Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
9.03
+0.02 (0.22%)
At close: Jan 15, 2026, 4:00 PM EST
8.97
-0.06 (-0.66%)
Pre-market: Jan 16, 2026, 9:23 AM EST
Aptevo Therapeutics Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for Aptevo Therapeutics in the last 12 months.
Price Target: n/a
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Aptevo Therapeutics.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $199,800 → $106,560 | Strong Buy | Maintains | $199,800 → $106,560 | +1,179,966.45% | Sep 23, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $40,439,520 → $11,721,600 | Buy | Maintains | $40,439,520 → $11,721,600 | +129,807,208.97% | May 13, 2022 |
| Roth Capital | Roth Capital | Strong Buy Maintains $37,509,120 → $29,304,000 | Strong Buy | Maintains | $37,509,120 → $29,304,000 | +324,518,172.43% | May 28, 2021 |
| Piper Sandler | Piper Sandler | Buy Maintains $18,754,560 → $40,439,520 | Buy | Maintains | $18,754,560 → $40,439,520 | +447,835,115.95% | Nov 11, 2020 |
| Roth Capital | Roth Capital | Strong Buy Initiates $98,461,440 | Strong Buy | Initiates | $98,461,440 | +1,090,381,295.35% | Apr 11, 2018 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-5.49
EPS Next Year
-1.63
from -5.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.65 | -1.68 | ||||
| Avg | -5.49 | -1.63 | ||||
| Low | -5.27 | -1.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.